Biotech / Synthetic Biology (Historical); Non-Operating Holding Company (Current)
Strategic Profile
Evolva positioned itself as a synthetic biology innovator with a differentiated technological approach compared to traditional pharmaceutical chemistry. The company leveraged discovery partnerships with major players like Roche while developing its own pipeline of compounds including resveratrol, vanilla, pomecin, stevia, and saffron. In January 2024, the company's operating assets were acquired by Danstar Ferment AG (subsidiary of Lallemand Inc.), fundamentally transforming its strategic position.
Cyborg Score Rationale
Post-acquisition in 2024, Evolva Holding SA became a shell company with no operating business. The company is pursuing M&A opportunities but lacks meaningful revenue-generating operations or pipeline. The name change to EvoNext Holdings in July 2025 reflects this transformation from biotech operator to investment vehicle.
Top Insights
Fundamental transition: Operating business acquired by Lallemand/Danstar Ferment in Jan 2024; Evolva now shell company pursuing M&A
Technology legacy: Developed proprietary precision fermentation platform for creating natural ingredients using synthetic biology; assets now owned by acquirer
Name change: Rebranded to EvoNext Holdings SA in July 2025, signaling strategic pivot from biotech to investment holding model
Delisting trajectory: Company announced intention to delist from SIX Swiss Exchange following acquisition completion
Named Competitors
Precision fermentation for natural ingredients — Synthetic biology platform for industrial biotech
Natural flavors and ingredients via biotech — Gene editing and synthetic biology applications
Recent Developments
(January 2024) Danstar Ferment AG (Lallemand subsidiary) completed acquisition of Evolva AG operating business
(December 2023) Evolva Holding shareholders approved acquisition by Danstar Ferment AG
(July 2025) Company name changed from Evolva Holding SA to EvoNext Holdings SA
Open the full interactive Evolva Holding SA report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.